In this episode of the Merge Medical Deep Dive Podcast, Drs. Jeff Brown and Jeff Cole speak with Rob Bohacs, Founder and CEO of Researchify Health.

Researchify Health is a revenue-stage AI company transforming clinical trial recruitment and patient engagement. Generating $900K in SaaS revenue in 2025, with a projected ARR of $1.3M by the end of next year, the company leverages AI-driven, SMS-based communication to streamline patient pre-screening, scheduling, and ongoing trial updates.

Researchify Health’s platform accelerates clinical trial participation, simplifies scheduling, and drives higher engagement through consistent follow-ups and AI study matching. This streamlined process guides patients seamlessly through their clinical trial journey, helping to bring drugs to market more rapidly.

Founded by seasoned clinical trial entrepreneurs with two prior exits, Researchify Health addresses key pain points in clinical trial enrollment. With a track record of innovation, the company is poised to become a leading AI platform in clinical trial engagement.

A visual overview of their solution can be found here: https://youtu.be/G3FQI-cic0E

Investment and Strategic Partner Opportunities:

Researchify Health has been founder-funded and is now seeking its first external capital raise of $800K through a convertible note, structured with a 5% annual interest rate, a 10% discount, and a $6.5M cap.

*****

Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum.

If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion.

Sign up today!

https://mergemedical.community.forum/

*****

DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.